Market position UroLift System is a minimally invasive BPH solution with no tissue cutting, heating, or removal, creating a differentiator in urology and potential appeal to surgeons seeking tissue-preserving options.

Strategic ownership Now under Teleflex since 2017, with established global distribution and resources, presenting opportunities to leverage Teleflex-wide channels, cross-sell adjacent urology and interventional products, and scale adoption.

Growth drivers Recent product evolution includes Advanced Tissue Control System launched in 2020 and a patient ambassador program in 2022, signaling ongoing innovations and demand-generation efforts that can be aligned with physician education and patient outreach campaigns.

Financial potential Revenue range of 25–50 million and a substantial funding cushion, indicating capacity to support channel expansion, larger sales teams, and multi-region deployments to accelerate market penetration.

Competitive landscape Identified as a competitor by iTind in 2026, highlighting a competitive market in BPH solutions and an opportunity to emphasize comparative advantages, clinical benefits, and patient quality-of-life improvements in sales pitches.